DEVELOPMENT OF AN IN VITRO BLOOD-BRAIN BARRIER

Information

  • Research Project
  • 3509269
  • ApplicationId
    3509269
  • Core Project Number
    R44NS028256
  • Full Project Number
    5R44NS028256-03
  • Serial Number
    28256
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1991 - 32 years ago
  • Project End Date
    8/31/1993 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1992 - 31 years ago
  • Budget End Date
    8/31/1993 - 30 years ago
  • Fiscal Year
    1992
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/11/1992 - 31 years ago
Organizations

DEVELOPMENT OF AN IN VITRO BLOOD-BRAIN BARRIER

The availability of pharmaceutical to combat neurological disorders is limited by the existence of the blood-brain barrier (BBB), a protective vascular system preventing most blood-borne molecules from entering the brain. Methods to transport drugs across the BBB would therefore be of enormous therapeutic and commercial value. The long-term goal of this project is to develop an in vitro model for the human BBB to serve as an experimental system for the discovery and evaluation of strategies for drug delivery to the brain. This model will consist of human brain microvascular endothelial cell cultures expressing BBB-associated properties. Phase i feasibility studies, in which these cells were isolated and grown on porous substrata, led to preliminary identification of culture conditions inducing the cell monolayer to restrict solute diffusion. Building upon these data, the development of an in vitro human BBB will continue in Phase II. The first aim will be to define the optimal culture environment for the in vitro human BBB, by screening culture components to identify those that promote the most restrictive cell monolayer. Once one or more culture conditions have been chosen, further studies will characterize the in vitro human BBB by testing it for several properties exhibited by the authentic BBB. These will include BBB-associated proteins, detected with immunological and functional assays, tight junctions, examined by electron microscopy, and specific transport systems that, in vivo, allow the brain to receive essential nutrients. These studies, by addressing the extent to which the in vitro human BBB mimics the BBB in vivo, should facilitate research, in Phase III and beyond, to apply this model as an experimental system for the design and testing of innovative drug delivery systems that circumvent the BBB.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R44
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    BPO
  • Study Section Name
    Biopsychology Study Section
  • Organization Name
    ALKERMES, INC.
  • Organization Department
  • Organization DUNS
    185481132
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024511420
  • Organization District
    UNITED STATES